Holen Sie sich die Stockscreener-App
3.18
9.28%
0.27
Handel nachbörslich:
3.20
0.02
+0.63%
Prime Medicine Inc Aktie (PRME) Neueste Nachrichten
Barclays PLC Increases Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
StockNews.com Upgrades Prime Medicine (NYSE:PRME) to Sell - MarketBeat
StockNews.com Upgrades Prime Medicine (NYSE:PRME) to “Sell” - Defense World
Prime Medicine Advances Gene Editing and Trials - TipRanks
Jane Street Group LLC Trims Stock Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Prime Medicine, Inc. (NYSE:PRME) Receives $12.67 Average Price Target from Analysts - Defense World
Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Prime Medicine (NYSE:PRME) Rating Increased to Sell at StockNews.com - Defense World
Prime Medicine (NYSE:PRME) Upgraded at StockNews.com - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Given Average Rating of "Buy" by Brokerages - MarketBeat
Geode Capital Management LLC Has $5.26 Million Stock Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Barclays PLC Boosts Stake in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now? - Insider Monkey
State Street Corp Buys 43,086 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World
Top 11 CRISPR Stocks to Invest In - Insider Monkey
12 Best Biotech Penny Stocks To Invest In Now - Insider Monkey
Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now? - Insider Monkey
10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey
Prime Medicine (NYSE:PRME) Upgraded to "Sell" at StockNews.com - MarketBeat
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans? - Simply Wall St
Prime Medicine's SWOT analysis: gene editing firm's stock faces pivotal 2025 - Investing.com
When Would Be The Best Time To Buy Prime Medicine Inc (NASDAQ: PRME) Stock? - Stocks Register
Prime Medicine, Inc. (NYSE:PRME) Receives $12.67 Consensus Price Target from Analysts - Defense World
Prime Medicine Files for Resale of 11 Million Shares - Marketscreener.com
Prime Medicine initiated with an Outperform at JMP Securities - MSN
Prime Medicine (NYSE:PRME) Stock Rating Upgraded by Citizens Jmp - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Fmr LLC Sells 184,541 Shares of Prime Medicine, Inc. (NYSE:PRME) - MarketBeat
Prime Medicine's SWOT analysis: gene editing firm's stock faces pivotal year - Investing.com Canada
Prime Medicine stock a top pick for gene editing, says JMP Securities - Investing.com Canada
Prime Medicine (NYSE:PRME) Now Covered by Analysts at JMP Securities - MarketBeat
Intech Investment Management LLC Acquires Shares of 14,102 Prime Medicine, Inc. (NYSE:PRME) - Defense World
Prime Medicine (NYSE:PRME) Earns Buy Rating from Guggenheim - Defense World
Vestal Point Capital LP Purchases 620,000 Shares of Prime Medicine, Inc. (NYSE:PRME) - MarketBeat
Comparing Century Therapeutics (NASDAQ:IPSC) & Prime Medicine (NYSE:PRME) - Defense World
Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies - Seeking Alpha
Oppenheimer & Co. Inc. Has $69,000 Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - Defense World
GSA Capital Partners LLP Invests $383,000 in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Brokerages Set Prime Medicine, Inc. (NYSE:PRME) Target Price at $13.25 - Defense World
1.44%
7.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):